Nektar Therapeutics (NASDAQ:NKTR – Get Rating) insider Jonathan Zalevsky sold 21,673 shares of the stock in a transaction dated Monday, May 16th. The stock was sold at an average price of $3.95, for a total transaction of $85,608.35. Following the completion of the sale, the insider now directly owns 276,399 shares in the company, valued at $1,091,776.05. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.
Jonathan Zalevsky also recently made the following trade(s):
- On Wednesday, February 16th, Jonathan Zalevsky sold 10,912 shares of Nektar Therapeutics stock. The stock was sold at an average price of $10.95, for a total transaction of $119,486.40.
NASDAQ NKTR opened at $3.94 on Wednesday. The firm’s 50 day moving average price is $5.22 and its 200-day moving average price is $9.78. Nektar Therapeutics has a 52-week low of $3.52 and a 52-week high of $19.37.
A number of analysts recently weighed in on NKTR shares. William Blair lowered shares of Nektar Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Monday, March 14th. Canaccord Genuity Group reduced their price objective on shares of Nektar Therapeutics from $25.00 to $6.00 and set a “buy” rating on the stock in a research report on Wednesday, March 16th. Cowen lowered shares of Nektar Therapeutics from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $35.00 to $8.00 in a research report on Monday, March 14th. StockNews.com raised shares of Nektar Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, May 12th. Finally, Canaccord Genuity Group dropped their target price on shares of Nektar Therapeutics from $25.00 to $6.00 and set a “buy” rating on the stock in a research note on Wednesday, March 16th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $13.46.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in NKTR. BlackRock Inc. boosted its stake in shares of Nektar Therapeutics by 41.5% during the fourth quarter. BlackRock Inc. now owns 26,671,803 shares of the biopharmaceutical company’s stock valued at $360,336,000 after purchasing an additional 7,827,559 shares in the last quarter. Norges Bank acquired a new stake in Nektar Therapeutics in the fourth quarter valued at approximately $23,878,000. Invesco Ltd. boosted its stake in Nektar Therapeutics by 3.4% in the fourth quarter. Invesco Ltd. now owns 36,891,494 shares of the biopharmaceutical company’s stock valued at $498,405,000 after acquiring an additional 1,220,307 shares in the last quarter. Woodline Partners LP acquired a new stake in Nektar Therapeutics in the fourth quarter valued at approximately $13,329,000. Finally, First Trust Advisors LP boosted its stake in Nektar Therapeutics by 28.4% in the first quarter. First Trust Advisors LP now owns 4,390,618 shares of the biopharmaceutical company’s stock valued at $23,665,000 after acquiring an additional 970,889 shares in the last quarter. Hedge funds and other institutional investors own 93.08% of the company’s stock.
Nektar Therapeutics Company Profile (Get Rating)
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19.
- Get a free copy of the StockNews.com research report on Nektar Therapeutics (NKTR)
- The Weber, Inc Growth Story Goes Up In Smoke
- Roku Stock is Repricing and Resetting Itself
- The Institutions Are Capping Gains In Take-Two Interactive
- Walmart’s “Everyday Low Prices” Gets Burned By Inflation
- VMWare Inc: Strong Revenues and Excellent Potential
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.